Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

NGENF NERVGEN PHARMA CORP

1.340
+0.115+9.39%
Close 09/30 16:00 ET
High
1.370
Open
1.250
Turnover
54.80K
Low
1.230
Pre Close
1.225
Volume
42.71K
Market Cap
78.45M
P/E(TTM)
Loss
52wk High
2.670
Shares
58.54M
P/E(Static)
Loss
52wk Low
1.100
Float Cap
78.45M
Bid/Ask %
0.00%
Historical High
2.670
Shs Float
58.54M
Volume Ratio
0.53
Historical Low
1.050
Dividend TTM
--
Div Yield TTM
--
P/B
10.89
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.07%
Amplitude
11.43%
Avg Price
1.283
Lot Size
1
Float Cap
78.45M
Bid/Ask %
0.00%
Historical High
2.670
Shs Float
58.54M
Volume Ratio
0.53
Historical Low
1.050
Dividend TTM
--
P/B
10.89
Dividend LFY
--
Turnover Ratio
0.07%
Amplitude
11.43%
Avg Price
1.283
Lot Size
1
Price Forecast

No Data

News

Comment

No More
Company Overview More
NervGen Pharma Corp., a regenerative medicine company, engages in the discovery, development, and commercialization of therapeutics for the treatment of nerve damage, including spinal cord injuries and peripheral nerve injuries. Its lead product candidate is the NVG-291 that is in clinical studies for the treatment of spinal cord injuries (SCI). It has a licensing agreement with Case Western Reserve University in Cleveland, Ohio to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. The company was founded by Brian J. McAlister and William Joseph Radvakon January 19, 2017 and is headquartered in Vancouver, Canada.
CEO: Mr. Paul Brennan
Market: Pink Market
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...